V1RG3 inhibitors represent a specialized class of chemical compounds designed to interact with and inhibit the activity of the V1RG3 protein. This protein is a component of the vacuolar-type H+-ATPase (V-ATPase) complex, which plays a vital role in maintaining cellular pH balance through the transport of protons across various intracellular membranes. The V1RG3 protein is part of the V1 domain of the V-ATPase, a crucial region responsible for the hydrolysis of ATP, the energy source required for the proton pumping function of the complex. The V1RG3 protein specifically contributes to the overall functionality and assembly of this multi-subunit enzyme complex.
Inhibitors targeting V1RG3 work by binding to this protein and disrupting its normal function within the V1 domain of the V-ATPase. This interaction can lead to alterations in the protein's ability to interact with other subunits of the V-ATPase complex or impair its ATPase activity. Consequently, such inhibitors interfere with the proton gradient maintenance and pH regulation that V-ATPase facilitates across intracellular compartments like endosomes and lysosomes. By targeting V1RG3, these inhibitors provide a means to explore the detailed roles of this protein in the broader context of cellular proton transport and pH homeostasis. The study of V1RG3 inhibitors can offer insights into the mechanistic aspects of V-ATPase function and the consequences of disrupting its assembly and activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | $91.00 $139.00 $374.00 | 36 | |
Dexamethasone is a glucocorticoid receptor agonist, which may downregulate V1R80 expression through modulation of gene transcription. | ||||||
Mifepristone | 84371-65-3 | sc-203134 | 100 mg | $61.00 | 17 | |
Mifepristone is a glucocorticoid receptor antagonist, potentially inhibiting the downregulation of V1R80 expression mediated by glucocorticoids. | ||||||
Fludrocortisone | 127-31-1 | sc-207690 | 50 mg | $454.00 | ||
Fludrocortisone is a glucocorticoid receptor agonist, potentially downregulating V1R80 expression through modulation of gene transcription. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib is a JAK1/2 inhibitor, potentially inhibiting signaling pathways involved in the regulation of V1R80 expression. | ||||||
Baricitinib | 1187594-09-7 | sc-364730 sc-364730A | 5 mg 25 mg | $200.00 $664.00 | ||
Baricitinib inhibits JAK1/2, which may lead to the inhibition of signaling pathways involved in the regulation of V1R80 expression. | ||||||
IKK-2 Inhibitor IV | 507475-17-4 | sc-203083 | 500 µg | $133.00 | 12 | |
TPCA-1 inhibits IKK-2, which may lead to the downregulation of NF-κB-mediated transcription of V1R80. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082 inhibits NF-κB activation, potentially reducing the transcriptional activity of NF-κB on V1R80 expression. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib inhibits NF-κB activation, potentially reducing the transcriptional activity of NF-κB on V1R80 expression. | ||||||
PI3K/HDAC Inhibitor | 1339928-25-4 | sc-364584 sc-364584A | 5 mg 10 mg | $347.00 $471.00 | ||
IKK-16 inhibits IKK-2, which may lead to the downregulation of NF-κB-mediated transcription of V1R80. | ||||||